BMY-28100 (カプセル剤) 連続投与時の体内動態

本廣 孝; 川上 晃; 佐々木 宏和; 荒巻 雅史; 阪田 保隆; 富永 薫; 山下 文雄; 中名生 宏; 平岡 聖樹; 石川 清康

doi:10.11553/antibiotics1968b.43.1893

PHARMACOKINETICS OF BMY-28100 IN MULTIPLE ADMINISTRATION

TAKASHI MOTOHIRO, AKIRA KAWAKAMI, HIROKAZU SASAKI, MASAFUMI ARAMAKI, YASUTAKA SAKATA, KAORU TOMINAGA, FUMIO YAMASHITA, HIROSHI NAKANOMYO, MASAKI HIRAOKA, KIYOYASU ISHIKAWA

Author information

TAKASHI MOTOHIRO
Department of Pediatrics, School of Medicine, Kurume University
AKIRA KAWAKAMI
Department of Pediatrics, School of Medicine, Kurume University
HIROKAZU SASAKI
Department of Pediatrics, School of Medicine, Kurume University
MASAFUMI ARAMAKI
Department of Pediatrics, School of Medicine, Kurume University
YASUTAKA SAKATA
Department of Pediatrics, School of Medicine, Kurume University
KAORU TOMINAGA
Department of Pediatrics, School of Medicine, Kurume University
FUMIO YAMASHITA
Department of Pediatrics, School of Medicine, Kurume University
HIROSHI NAKANOMYO
Preclinical Research Laboratories, Bristol-Myers Research Institute, Ltd.
MASAKI HIRAOKA
Preclinical Research Laboratories, Bristol-Myers Research Institute, Ltd.
KIYOYASU ISHIKAWA
Preclinical Research Laboratories, Bristol-Myers Research Institute, Ltd.

JOURNAL FREE ACCESS

1990 Volume 43 Issue 11 Pages 1893-1897

DOI https://doi.org/10.11553/antibiotics1968b.43.1893

Details

Abstract

A multiple dose trial of BMY-28100, a new oral cephalosporin, was performed in volunteers, in order to evaluate its safety and pharmacokinetics.
BMY-28100 was administered orally 250 mg t. i. d. for 7 days to seven healthy adult males.
No side effects nor abnormal laboratory findings were observed.
Peak levels of serum concentration and half-lives after the first and 19th administrations were 4.45 and 4.83, μg/ml and 1.3 and 1.1 hours, respectively.
Urinary recoveries in 24 hours were 53.4% on day 1 and 56.2% on day 7.
There was no tendency towards accumulation in blood upon continuous daily dosing of 250 mg t. i. d.

Corresponding author

Register with J-STAGE for free!